Ivosidenib and Azacitidine inIDH1-Mutated AML

  • Goodman, Aaron M. M.D.
  • Mohyuddin, Ghulam Rehman M.D.
  • Prasad, Vinay M.D., M.P.H.

  • 1University of California San Diego La Jolla, CA [email protected]

    2University of Utah Salt Lake City, UT

    3University of California San Francisco San Francisco, CA

Dr. Goodman reports receiving consulting fees from Seattle Genetics (now Seagen) and EUSA Pharma. No other potential conflict of interest relevant to this letter was reported.

New England Journal of Medicine 386(26):p 2536, June 30, 2022.
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF